These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 30005109)

  • 21. Toward Better-Quality Compounded Drugs - An Update from the FDA.
    Woodcock J; Dohm J
    N Engl J Med; 2017 Dec; 377(26):2509-2512. PubMed ID: 29281577
    [No Abstract]   [Full Text] [Related]  

  • 22. Compounding topicals in dermatology.
    Shabeeb N
    Cutis; 2020 May; 105(5):E25-E26. PubMed ID: 32603403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analytic Methods Used in Quality Control in a Compounding Pharmacy.
    Allen LV
    Int J Pharm Compd; 2017; 21(1):31-37. PubMed ID: 28346196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving the Quality of Compounded Sterile Drug Products: A Historical Perspective.
    Cantrell SA
    Ther Innov Regul Sci; 2016 May; 50(3):266-269. PubMed ID: 30227062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Considerations before choosing (extemporaneously) compounded products.
    Krochmal L
    Dermatol Ther; 2009; 22(3):225-8. PubMed ID: 19453346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compounding our problems--again.
    Trissel LA
    Am J Health Syst Pharm; 2003 Mar; 60(5):432. PubMed ID: 12635448
    [No Abstract]   [Full Text] [Related]  

  • 27. Compounding is still appropriate in clinical practice.
    Thiers BH
    Dermatol Clin; 1998 Apr; 16(2):329-30. PubMed ID: 9589206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Federal court strikes down compounding regulations.
    Harteker LR
    Am J Health Syst Pharm; 2001 Apr; 58(8):638, 640, 643. PubMed ID: 11329752
    [No Abstract]   [Full Text] [Related]  

  • 29. Regulations, liability, safety, and economics related to compounding.
    Campbell EH; Elston DM; Straughan CL; Antonovich DD
    J Am Acad Dermatol; 2020 Jul; 83(1):184-188. PubMed ID: 31821858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introduction to Quality Control in a Compounding Pharmacy.
    Allen LV
    Int J Pharm Compd; 2016; 20(6):481-484. PubMed ID: 28339387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Choosing a Vial Processing Line for Aseptic Compounding: Part 1.
    Noorian S; Vahedi N
    Int J Pharm Compd; 2016; 20(4):283-292. PubMed ID: 28333673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adventures in the Environmental World and Environmental Microbiology Sampling of Air for Pharmaceutical Sterile Compounding.
    Ligugnana R
    Int J Pharm Compd; 2017; 21(3):182-190. PubMed ID: 28557779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Registrations of compounding outsourcing facilities trickle in.
    Thompson CA
    Am J Health Syst Pharm; 2014 Mar; 71(5):350, 352. PubMed ID: 24534584
    [No Abstract]   [Full Text] [Related]  

  • 34. Déjà vu all over again!
    Allen LV
    Int J Pharm Compd; 2014; 18(3):180. PubMed ID: 25306763
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA Expands List of "Do Not Compound" Drug Products.
    Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services
    J Pain Palliat Care Pharmacother; 2017 Mar; 31(1):76-78. PubMed ID: 28287350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
    Hung JC; Augustine SC; Cheng KT; Green RL; Hopkins WM; Laven DL; Nelson BR; Petry NA; Ponto JA; Quinton TM; Swanson DP
    J Am Pharm Assoc (Wash); 2002; 42(5):789-98. PubMed ID: 12269713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sterility of extemporaneously compounded preservative-free injections.
    Levchuk JW
    Am J Hosp Pharm; 1991 Jan; 48(1):71-2. PubMed ID: 2053941
    [No Abstract]   [Full Text] [Related]  

  • 38. The "Lists": What Do They Mean?
    Voliva J
    Int J Pharm Compd; 2016; 20(6):477-479. PubMed ID: 28339386
    [No Abstract]   [Full Text] [Related]  

  • 39. Distinguishing between compounding facilities and the development of the 503B bulk drug substance list.
    Gianturco SL; Mattingly AN
    J Am Pharm Assoc (2003); 2021; 61(1):e8-e11. PubMed ID: 32713748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. U.S. Food and Drug Administration requests for input on HR 3204 enactment: the Drug Quality and Security Act of 2013.
    Miller DG
    Int J Pharm Compd; 2014; 18(1):35-6. PubMed ID: 24881338
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.